Thus, a histopathological-level, a test that allows the recognition of discordance between HER2 gene amplification and protein expression simultaneously, could improve the clinical selection of patients for anti-HER2 therapies, due to a better accuracy of the HER2 IHT in the HER2+ BC. Here, ERBB2 is linked to breast cancer.